May 2, 2022 -- At the recent American Association for Cancer Research (AACR) meeting in New Orleans, Scienceboard.net spoke with the University of Tübingen’s Dr. Juliane Walz, professor of peptide-based immunotherapies, and research associate Claudia Tandler about the promising results their CoVac-1 vaccine has shown in immunocompromised patients.
Walz's team used their expertise with cancer therapeutics to develop a vaccine that induces T cells in immunocompromised patients who do not produce an adequate immune response to other vaccines.
The unit's research has shown that the vaccine induced generation of T cells in healthy volunteers much more effectively than either previous COVID infection or other vaccines. The effect was long lasting and was not diminished with any of the known COVID-19 variants, such as omicron.
A trial with a cohort of immunocompromised patients showed effective T-cell response in 86% of the patients and distinctly higher T-cell response than with current approved vaccines. The team is now looking forward to phase III approval trials and deciding how the vaccine will be further developed.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
